STAMPEDE prostate cancer trial closes after reshaping global treatment practice
Cancer Research UK reflects on the STAMPEDE trial's closure and its practice-changing legacy for men with advanced prostate cancer.
Cancer Research UK has published a long-read retrospective examining the STAMPEDE trial, which wound down earlier in 2026 after more than a decade of operation. STAMPEDE — Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy — was an adaptive, multi-arm, multi-stage platform trial that ran across numerous UK hospitals and international sites.
The trial's adaptive design allowed researchers to test several treatments simultaneously against a shared control arm, dramatically improving efficiency compared with running separate trials for each agent. Over its lifetime, STAMPEDE generated evidence that influenced international clinical guidelines on the treatment of newly diagnosed metastatic and high-risk localised prostate cancer, including the adoption of upfront combination hormone therapy regimens.
Cancer Research UK's retrospective traces the origins of the trial's design — described at the time as a 'mad thought' by some — through to its scientific and clinical outputs. The piece does not constitute guidance for individual patients; it documents the history and published evidence base of a major publicly funded trial. For oncologists and researchers, the STAMPEDE body of work remains a reference point for platform trial methodology and for the evidence underpinning current prostate cancer management approaches.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Cancer Research UK · 2026-11-17The 'mad thought' that changed millions of lives